MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Use with caution

Co-careldopa 10mg/100mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 10mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 10mg/100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 10mg/100mg tablets (Bristol Laboratories Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 10mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 10mg/100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 10mg/100mg tablets (Medihealth (Northern) Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 10mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 10mg/100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 10mg/100mg tablets (Sigma Pharmaceuticals Plc)

Explore other Co-careldopa formulations Explore other Co-careldopa 10mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 10mg/100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 10mg/100mg tablets (Somex Pharma)

Explore other Co-careldopa formulations Explore other Co-careldopa 10mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 10mg/100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 10mg/100mg tablets (Teva UK Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 10mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 10mg/100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 12.5mg/50mg tablets (A A H Pharmaceuticals Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 12.5mg/50mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 12.5mg/50mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 12.5mg/50mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 12.5mg/50mg tablets (Bristol Laboratories Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 12.5mg/50mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 12.5mg/50mg tablets (Medihealth (Northern) Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 12.5mg/50mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 12.5mg/50mg tablets (Orion Pharma (UK) Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 12.5mg/50mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 12.5mg/50mg tablets (Somex Pharma)

Explore other Co-careldopa formulations Explore other Co-careldopa 12.5mg/50mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 12.5mg/50mg tablets (Strides Pharma UK Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 12.5mg/50mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet 12.5mg/50mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 25mg/100mg tablets (A A H Pharmaceuticals Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 25mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet Plus 25mg/100mg tablets (Organon Pharma (UK) Ltd).

Use with caution

Co-careldopa 25mg/100mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Co-careldopa formulations Explore other Co-careldopa 25mg/100mg tablets suppliers

Stability Notes

Complex dosing regime. Protect from moisture. Max 7 days in MCA.

Provenance

This compatibility recommendation is derived from Sinemet Plus 25mg/100mg tablets (Organon Pharma (UK) Ltd).

Print this list

Compatible

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.

Use with caution

Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.

Incompatible

Medicines under this category are not suitable for use inside MCAs.

No Stability Information

We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.